Latest news with #AuroraCannabisInc
Yahoo
07-05-2025
- Business
- Yahoo
Higher Returns with Aurora Cannabis
By Rayk Riechmann Investors want what they're on! Aurora Cannabis Inc. (Nasdaq: ACB), a federally-licensed producer of medical and consumer cannabis, is attractively positioned as an early leader in global regulated markets. ACB leverages a best-in-class brand portfolio to grow and sell products across all major cannabis categories. And it's translating to results: the company just delivered a top-down beat on strengthening industry tailwinds and expanding global sales. With a strong footprint in key medical cannabis markets in North America, Europe, and Australia, the company excels at meeting both patient and regulatory demands. This early adaptation of medical markets is already paying off with strong revenue growth and creates a first-mover advantage once these regions transform into recreational markets. Germany is close to creating a national legalized consumer market, and as other European nations follow suit, top-line growth could skyrocket. ACB is strategically positioned to rapidly expand into new markets within Europe as regulatory liberalization continues. Notably, a local presence in these markets mostly shields ACB from tariff-related uncertainty. Here's ACB's global presence in one glance: #1 in Canadian medical market share, #2 in Australia following the acquisition of MedReleaf Australia in 2024, #3 in Poland, and one of only three companies licensed to cultivate in Germany. Since June 2021, ACB has introduced 24 new proprietary strains, which drive yield, potency, and cost-efficiency. Newly engineered next-gen cultivars appeal to consumers with increased consistency and save up to 30% in per-unit costs. Both are key differentiators in the consumer and medical market. ACB's one-of-a-kind combination of regulatory expertise, brand architecture, and scientific innovation enables superior financial performance, as demonstrated in the top-down beat delivered in the latest quarter, driven mainly by a 51% increase in international medical cannabis revenue. The debt-free cannabis business has taken decisive steps to ensure profitable growth moving forward. By rightsizing its SG&A expenses and consolidating its manufacturing footprint, ACB delivered positive net-income for the second time in company history, as well as record adjusted EBITDA and FCF. Our bullish outlook for 2025 is fueled by improved company profitability and favorable external forces. ACB currently trades at a NTM price/sales multiple of 0.96x – a big discount to its own 3-year mean multiple of 1.51x, indicating that the stock price has not caught up to recent developments and is due for a rerating. What's more, ACB trades at a significant discount to almost all peers on an Ebitda basis.
Yahoo
02-05-2025
- Business
- Yahoo
Is Aurora Cannabis Inc. (ACB) Among the Best Tobacco and Cigarette Stocks to Buy Now?
We recently compiled a list of the 10 Best Tobacco and Cigarette Stocks to Buy Now. In this article, we are going to take a look at where Aurora Cannabis Inc. (NASDAQ:ACB) stands against the other Tobacco and Cigarette stocks. Cigarette and tobacco stocks are companies that produce and sell cigars, snuff, chewing tobacco, cigarettes, e-cigarettes, and all other tobacco products. The tobacco industry has long been a huge winner for investors. Tobacco companies were among the top performers during the 20th century because of their reputation for providing investors with substantial dividend yields as well as their addictive, extremely profitable, and recession-proof product. However, tobacco firms now confront a different set of challenges. Globally, smoking rates have been progressively declining, particularly in the United States, as a result of growing legislation and health concerns. The industry has attempted to shift to next-generation products as a result. Some people believe that e-cigarettes, vaporizers, and chewable nicotine pouches are healthier options since they avoid some of the negative aspects of smoking cigarettes, such as unpleasant odors. Some companies are expanding beyond tobacco, working with cannabis businesses to capitalize on the potential development in a market that shares numerous similarities with tobacco. There are other hazards associated with tobacco stocks, such as heightened regulation and a decline in smoking rates. According to the Centers for Disease Control and Prevention, the number of tobacco farms in the United States decreased from 93,530 in 1997 to roughly 3,000 in 2022. Nonetheless, the USA was the world's fifth-largest producer of tobacco in 2021, harvesting 431.6 million pounds in 2022, compared to 1.74 billion pounds in 1997. Seventy-seven percent of U.S. production came from North Carolina or Kentucky. Price reductions accounted for $5.7 billion (72%) of the $8.6 billion tobacco businesses spent on advertising in 2022, which included $572.7 million for smokeless tobacco and $8.01 billion for cigarettes. Marketing costs for e-cigarettes came to $859.4 million in 2021. Sales of cigarette packs fell from 12.5 billion to 9.1 billion packs between 2015 and 2021, a 27% decrease. In 2024, the average cigarette tax in each state was $1.93, while the federal tax was $1.01. Despite the industry's weak revenue and profit development, investors continue to be drawn to these stocks due to their consistent dividends, profitability, and solid profit margins. Investors believe that stronger growth will eventually be catalyzed by next-generation products. However, on April 2, 2025, the U.S. Supreme Court upheld the FDA's decision to deny approval for flavored e-cigarettes in a major decision. According to Justice Samuel Alito, vape producers were given 'adequate notice' of the FDA's review criteria. In this case, businesses like Vapetasia and Triton Distribution applied for certification for products such as 'Mother's Milk and Cookies' and 'Killer Kustard Blueberry.' The FDA has been regulating vaping products since 2016, claiming that flavored vapes represent a health concern and may encourage young people to use tobacco. More than 2.1 million youths in the US reported using e-cigarettes in 2023, with 10% of high school students vaping. The FDA has rejected thousands of flavored products and has only approved tobacco and menthol flavors. One specific issue, marketing plan consideration, was returned to lower courts after the Supreme Court reversed the 5th Circuit's prior criticism of the FDA's changing criteria. Companies that promote unapproved products risk 'civil and criminal penalties,' the FDA warned. A modern cannabis retail store with a wide selection of products and vaporizers. For this article, we sifted through the online rankings to form an initial list of the 15 Tobacco and Cigarette Stocks. We have also included e-cigarette and cannabis companies. From the resultant dataset, we chose 10 stocks with the highest number of hedge fund investors, using Insider Monkey's database of 1009 hedge funds in Q4 2024 to gauge hedge fund sentiment for stocks. We have used the stock's market cap as of April 25, 2025, as a tie-breaker in case two or more stocks have the same number of hedge funds invested. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here). Number of Hedge Fund Holders: 6 Aurora Cannabis Inc. (NASDAQ:ACB), a Canadian company with its headquarters located in Edmonton, grows and markets cannabis for both medical and recreational purposes under several brands, including Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company is largely based in Canada, it has expanded globally through medical cannabis export agreements. It is one of the Best Tobacco Stocks. The third quarter of 2025 was a strong period for Aurora Cannabis Inc. (NASDAQ:ACB), as its earnings per share of $0.41 greatly exceeded forecasts by $0.42. The business produced a record adjusted EBITDA of $23.1 million, up 316% YoY, and a record net income of $31.2 million, up 282% YoY. Furthermore, Q3 revenue exceeded projections by 28.73% YoY to $61.62 million, led by record-breaking global medical net revenue. The company's globalization plan is working; its overseas sales climbed by 112% in the medical cannabis industry. International revenue outpaced Canadian medicinal cannabis for the second consecutive quarter. In 2025, ACB also produced $27.4 million in free cash flow during the third quarter. Setting new benchmarks in cannabis science, Aurora Cannabis Inc. (NASDAQ:ACB) operates a top-notch genetics and research facility in Canada. The business recently revealed that it has found a new genetic source of resistance to powdery mildew in cannabis sativa, which offers strong protection against this pathogen. The innovation, which is currently being used in its breeding program, provides a vital answer to a major problem facing the cannabis business globally. Overall, ACB ranks 10th on our list of the 10 Best Tobacco and Cigarette Stocks to Buy Now. While we acknowledge the potential of Tobacco and Cigarette companies, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ACB but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
30-04-2025
- Business
- Yahoo
Aurora Cannabis Announces the Completion of a Multimillion Dollar Investment and Renaming of B.C. Manufacturing Facility
NASDAQ | TSX: ACB Company's Long-Standing Investment in Operational Excellence Continues with Industry Leading Upgrades and Renaming the Facility to Aurora Alpine EDMONTON, AB, April 30, 2025 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces the completion of a multi-year investment of $3 million in improvements to its manufacturing facility in Pemberton, British Columbia. These upgrades are a combination of Aurora's proprietary high-performing genetics and state-of-the-art engineering design which have resulted in optimal cultivation conditions, expanded output, and superior product quality. The site has been renamed to Aurora Alpine – a testament to the site reaching its highest potential and to reflect the facility overlooking Mount Currie in the Pemberton Valley. "Over the last three years, the investments we've made into this facility have resulted in doubling the yield and potency, reaching a record 33.7%," says Alex Miller, Executive Vice President of Operations and Supply Chain at Aurora. "The name Aurora Alpine reflects our commitment to achieving the highest degree of excellence at a site that's driven by industry leading genetic technology, and backed by a world-class team that make it all possible." The former Whistler Medical Marijuana Company site was licensed in 2019 and was built on a legacy of producing award-winning cannabis. The GACP certified facility enables Aurora to expand its global reach by exporting premium medical cannabis produced from the Aurora Alpine site internationally. Aurora continues to advance the frontiers of operational excellence through the integration of cutting-edge cultivation technologies and proprietary genetics. These advancements have not only increased manufacturing capabilities, but have also set new industry standards for operational efficiency and cultivation precision. These continuous improvements are what solidifies Aurora as a global leader that continues to shape the future of the cannabis industry. About Aurora Cannabis Inc. Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at and follow us on X and LinkedIn. Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB". Contact For Media: Michelle Lefler | VP, Communications & PR | media@ For Investors: ICR, Inc. | aurora@ Forward Looking Information This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's improvements at its facility located in Pemberton, BC and the anticipated benefits, including expanded capacity, superior growing practices, optimal cultivating conditions, and the ability for Aurora to expand its global reach by exporting premium medical cannabis produced from that facility internationally, as well as statements regarding the Company's commitment to continuous improvement and operational excellence. These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 20, 2024 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at and filed with and available on the SEC's website at The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. View original content to download multimedia: SOURCE Aurora Cannabis Inc. View original content to download multimedia:
Cision Canada
30-04-2025
- Business
- Cision Canada
Aurora Cannabis Announces the Completion of a Multimillion Dollar Investment and Renaming of B.C. Manufacturing Facility
NASDAQ| TSX: ACB Company's Long-Standing Investment in Operational Excellence Continues with Industry Leading Upgrades and Renaming the Facility to Aurora Alpine EDMONTON, AB, April 30, 2025 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces the completion of a multi-year investment of $3 million in improvements to its manufacturing facility in Pemberton, British Columbia. These upgrades are a combination of Aurora's proprietary high-performing genetics and state-of-the-art engineering design which have resulted in optimal cultivation conditions, expanded output, and superior product quality. The site has been renamed to Aurora Alpine – a testament to the site reaching its highest potential and to reflect the facility overlooking Mount Currie in the Pemberton Valley. "Over the last three years, the investments we've made into this facility have resulted in doubling the yield and potency, reaching a record 33.7%," says Alex Miller, Executive Vice President of Operations and Supply Chain at Aurora. "The name Aurora Alpine reflects our commitment to achieving the highest degree of excellence at a site that's driven by industry leading genetic technology, and backed by a world-class team that make it all possible." The former Whistler Medical Marijuana Company site was licensed in 2019 and was built on a legacy of producing award-winning cannabis. The GACP certified facility enables Aurora to expand its global reach by exporting premium medical cannabis produced from the Aurora Alpine site internationally. Aurora continues to advance the frontiers of operational excellence through the integration of cutting-edge cultivation technologies and proprietary genetics. These advancements have not only increased manufacturing capabilities, but have also set new industry standards for operational efficiency and cultivation precision. These continuous improvements are what solidifies Aurora as a global leader that continues to shape the future of the cannabis industry. About Aurora Cannabis Inc. Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at and follow us on X and LinkedIn. Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB". Contact For Investors: ICR, Inc. | [email protected] Forward Looking Information This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law (" forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's improvements at its facility located in Pemberton, BC and the anticipated benefits, including expanded capacity, superior growing practices, optimal cultivating conditions, and the ability for Aurora to expand its global reach by exporting premium medical cannabis produced from that facility internationally, as well as statements regarding the Company's commitment to continuous improvement and operational excellence. These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 20, 2024 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at and filed with and available on the SEC's website at The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
Yahoo
31-03-2025
- Business
- Yahoo
Aurora Cannabis Recognized for Executive Gender Diversity by The Globe and Mail
Canada's Largest Medical Cannabis Company is an Honouree in The Globe and Mail's 2025 Report on Business Magazine's sixth annual Women Lead Here List EDMONTON, AB, March 31, 2025 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, has been named an honouree on the Globe & Mail's 2025 Report on Business, Women Lead Here list. This annual editorial benchmark recognizes the top publicly traded Canadian companies with the highest gender diversity at the executive level. "As a company with a leading purpose of being empowered by people, this recognition demonstrates how we are committed to creating an environment where everyone is inspired to strive for excellence," says Simona King, Chief Financial Officer at Aurora. "With 43% of our executive leadership team being women, together the women of Aurora are driving change, breaking barriers and shaping the future for women in the medical cannabis industry." In 2022, the company established the Women Empowerment Network (WEN) – an employee resource group designed to bring together the global Aurora team to enrich the advancement of women. WEN, along with other affinity groups, is open to all employees and offers frequent learning and community engagement opportunities that support personal and professional growth. Aurora is proud to foster a diverse community of industry-leading professionals. As a company that prioritizes cultivating great talent, together the global organization empowers everyone to be their authentic selves, celebrate their differences and continue creating a more equitable and inclusive future. The 2025 Women Lead Here list is published in the April 2025 issue of Report on Business magazine, distributed with The Globe and Mail on March 29, 2025, and online at About Aurora Cannabis Inc. Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at and follow us on X and LinkedIn. Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB". Contact For Investors: ICR, Inc. | aurora@ About The Globe and Mail The Globe and Mail is Canada's foremost news media company, leading the national discussion and causing policy change through brave and independent journalism since 1844. With our award-winning coverage of business, politics and national affairs, The Globe and Mail newspaper reaches 6.1 million readers every week in our print or digital formats, and Report on Business magazine reaches 2.8 million readers in print and digital every issue. Our investment in innovative data science means that as the world continues to change, so does The Globe. The Globe and Mail is owned by Woodbridge, the investment arm of the Thomson family. Forward Looking Information This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 20, 2024 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at and filed with and available on the SEC's website at The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. View original content to download multimedia: SOURCE Aurora Cannabis Inc. View original content to download multimedia:
